Clinical trials
Phase 2 Mastocytosis, Systemic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Jason Robert Gotlib | 3 |
| M.D. Anderson Cancer Center | 3 |
| Blueprint Medicines Corporation | 2 |
| Cogent Biosciences, Inc. | 2 |
| Novartis Pharmaceuticals | 2 |
| City of Hope Medical Center | 1 |
| Federico II University | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Patara Pharma | 1 |
| Telios Pharma, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mastocytosis, Systemic | 18 |
| Leukemia, Mast-Cell | 7 |
| Leukemia | 4 |
| Mastocytosis | 4 |
| Hematologic Diseases | 2 |
| Hematologic Neoplasms | 2 |
| Hypersensitivity | 2 |
| Immune Complex Diseases | 2 |
| Immune System Diseases | 2 |
| Leukemia, Myelomonocytic, Chronic | 2 |
Trials
Showing 26 to 18 of 18. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.